



## Amendment of Results of Annual General Meeting

**MELBOURNE Australia 25 November 2020:** Prescient Therapeutics Limited (Prescient; ASX: PTX) advises the voting results of the Annual General Meeting held on 24 November 2020 have been amended due to a minor and immaterial miscalculation of percentages. It is noted that there is no change to the number of votes cast and all resolutions were passed by way of a poll.

– Ends –

### About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

#### Cell Therapies

**OmniCAR:** is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens.

OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

**Cell Therapy:** Prescient has several other initiatives underway to develop new cell therapy approaches.

#### Targeted Therapies

**PTX-100** is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed to be the only RhoA inhibitor in the world in clinical development. PTX-100 is currently in a PK/PD basket study of hematological and solid malignancies, focusing on cancers with Ras and RhoA mutations. In a previous Phase 1 trial in advanced solid tumours, PTX-100 was well tolerated and achieved stable disease.

**PTX-200** is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound has encouraging Phase 2a data in HER2-negative breast cancer; Phase 1b/2 in relapsed and refractory AML and Phase 1b in recurrent or persistent platinum resistant ovarian cancer:

#### COVID-19 Therapies

Two assets are being assessed by the Doherty Institute for antiviral activity against SARS-CoV-2, the virus that causes COVID-19 disease.



Find out more at [ptxtherapeutics.com](http://ptxtherapeutics.com), or connect with us via Twitter [@PTX\\_AUS](https://twitter.com/PTX_AUS) and [LinkedIn](https://www.linkedin.com/company/ptxtherapeutics).

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

**For more information please contact:**

Steven Yatomi-Clarke  
CEO & Managing Director  
Prescient Therapeutics  
[steven@ptxtherapeutics.com](mailto:steven@ptxtherapeutics.com)

**Investor enquiries:**  
Warrick Lace – Reach Markets  
+61 404 656 408  
[warrick.lace@reachmarkets.com.au](mailto:warrick.lace@reachmarkets.com.au)

**Media enquiries:**  
Andrew Geddes – CityPR  
+61 2 9267 4511  
[ageddes@citypublicrelations.com.au](mailto:ageddes@citypublicrelations.com.au)

**Disclaimer and Safe Harbor Statement**

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited (“Prescient” or the “Company”), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words ‘estimate’, ‘project’, ‘intend’, ‘expect’, ‘plan’, ‘believe’, ‘guidance’, and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management’s current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.



This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

### **Supplemental COVID-19 Risk Factors**

Please see our website : [Supplemental COVID-19 Risk Factors](#)

24 November 2020

ASX Limited  
Market Announcements Office  
Level 10  
20 Bond Street  
SYDNEY NSW 2000

Dear Sir/Madam

**RESULTS OF 2020 ANNUAL GENERAL MEETING**

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

Yours sincerely,

**PRESCIENT THERAPEUTICS LIMITED**



**Melanie Leydin**  
**Company Secretary**

**Prescient Therapeutics Limited**  
**2020 Annual General Meeting**  
**Tuesday, 24 November 2020**  
**Voting Results**

The following information is provided in accordance with section 251AA(2) of Corporations Act 2001 (Cth)

Resolution Details				Show of Hands or Poll	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Res. Results
Resolution		Res. Type	If s250U applies	S or P	For	Against	Proxy's Discretion	Abstain/ Excluded	For	Against	Abstain*	Carried / Not Carried
1	Adoption of Remuneration Report	Ordinary	N/A	P	141,028,679 96.58%	2,276,151 1.56%	2,722,926 1.86%	3,790,812 -	145,457,043 98.46%	2,276,151 1.54%	5,813,812 -	Carried
2	Election of Dr Allen Ebens as a Director of the Company	Ordinary	N/A	P	146,092,873 97.55%	922,779 0.62%	2,744,916 1.83%	58,000 -	152,543,227 99.40%	922,779 0.60%	81,000 -	Carried
3	Re-election of Mr Steven Engle as a Director of the Company	Ordinary	N/A	P	145,974,677 97.54%	929,375 0.62%	2,744,916 1.83%	169,600 -	152,425,031 99.39%	929,375 0.61%	192,600 -	Carried
4	Approval to grant Options to Mr Steven Yatomi-Clarke (or his nominee)	Ordinary	N/A	P	73,927,614 50.57%	69,486,678 47.53%	2,767,672 1.89%	3,636,604 -	78,082,548 52.88%	69,586,678 47.12%	5,877,780 -	Carried
5	Approval to grant Options to Mr Steven Engle (or his nominee)	Ordinary	N/A	P	73,867,624 50.53%	69,579,668 47.60%	2,734,672 1.87%	3,636,604 -	78,307,734 52.95%	69,579,668 47.05%	5,659,604 -	Carried
6	Approval to grant Options to Dr James Campbell (or his nominee)	Ordinary	N/A	P	73,927,614 50.57%	69,519,678 47.56%	2,734,672 1.87%	3,636,604 -	78,049,548 52.85%	69,619,678 47.15%	5,877,780 -	Carried

Resolution Details				Show of Hands or Poll	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Res. Results
Resolution		Res. Type	If s250U applies		S or P	For	Against	Proxy's Discretion	Abstain/ Excluded	For	Against	Abstain*
7	Approval to grant Options to Dr Allen Ebens (or his nominee)	Ordinary	N/A	P	73,867,614 50.53%	69,579,678 47.60%	2,734,672 1.87%	3,636,604 -	78,307,724 52.95%	69,579,678 47.05%	5,659,604 -	Carried
8	Ratification of Appointment of Auditor	Ordinary	N/A	P	146,139,279 97.63%	798,773 0.53%	2,744,916 1.83%	135,600 -	152,589,633 99.48%	798,773 0.52%	158,600 -	Carried
9	Ratification of Prior Issue of 128,110,565 Fully Paid Ordinary Shares	Ordinary	N/A	P	112,911,008 96.53%	1,295,204 1.11%	2,759,916 2.36%	32,852,440 -	119,376,362 98.93%	1,295,204 1.07%	32,875,440 -	Carried
10	Renewal of Proportional Takeover Provision	Special	N/A	P	144,892,028 96.92%	1,854,024 1.24%	2,744,916 1.84%	327,600 -	151,342,382 98.79%	1,854,024 1.21%	350,600 -	Carried
11	Approval of Amendments to the Constitution	Special	N/A	P	145,247,718 97.41%	1,096,698 0.74%	2,759,916 1.85%	714,236 -	150,213,072 99.28%	1,096,698 0.72%	737,236 -	Carried
12	Approval of 10% Placement Facility	Special	N/A	P	145,120,401 96.98%	1,775,184 1.19%	2,744,916 1.83%	178,067 -	149,970,755 98.77%	1,875,184 1.23%	201,067 -	Carried

\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.